Correlation of tumor PD-L1 expression in different tissue types and outcome of PD-1-based immunotherapy in metastatic melanoma – analysis of the DeCOG prospective multicenter cohort study ADOREG/TRIM

BACKGROUND: PD-1-based immune checkpoint inhibition (ICI) is the major backbone of current melanoma therapy. Tumor PD-L1 expression represents one of few biomarkers predicting ICI therapy outcome. The objective of the present study was to systematically investigate whether the type of tumor tissue e...

Descripción completa

Detalles Bibliográficos
Autores principales: Placke, Jan-Malte, Kimmig, Mona, Griewank, Klaus, Herbst, Rudolf, Terheyden, Patrick, Utikal, Jochen, Pföhler, Claudia, Ulrich, Jens, Kreuter, Alexander, Mohr, Peter, Gutzmer, Ralf, Meier, Friedegund, Dippel, Edgar, Welzel, Julia, Engel, Daniel Robert, Kreft, Sophia, Sucker, Antje, Lodde, Georg, Krefting, Frederik, Stoffels, Ingo, Klode, Joachim, Roesch, Alexander, Zimmer, Lisa, Livingstone, Elisabeth, Hadaschik, Eva, Becker, Jürgen C., Weichenthal, Michael, Tasdogan, Alpaslan, Schadendorf, Dirk, Ugurel, Selma
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10483509/
https://www.ncbi.nlm.nih.gov/pubmed/37660535
http://dx.doi.org/10.1016/j.ebiom.2023.104774

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10483509/
https://www.ncbi.nlm.nih.gov/pubmed/37660535
http://dx.doi.org/10.1016/j.ebiom.2023.104774

Ejemplares similares